WO2018105805A1 - Procédé d'isolement d'un îlot de porc nouveau-né - Google Patents
Procédé d'isolement d'un îlot de porc nouveau-né Download PDFInfo
- Publication number
- WO2018105805A1 WO2018105805A1 PCT/KR2017/000273 KR2017000273W WO2018105805A1 WO 2018105805 A1 WO2018105805 A1 WO 2018105805A1 KR 2017000273 W KR2017000273 W KR 2017000273W WO 2018105805 A1 WO2018105805 A1 WO 2018105805A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- islets
- islet
- npccs
- newborn
- enzyme
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 210000000496 pancreas Anatomy 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- 230000004913 activation Effects 0.000 claims abstract description 8
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 241000282887 Suidae Species 0.000 claims description 20
- 229940088598 enzyme Drugs 0.000 claims description 17
- 238000000926 separation method Methods 0.000 claims description 16
- 102000029816 Collagenase Human genes 0.000 claims description 10
- 108060005980 Collagenase Proteins 0.000 claims description 10
- 229960002424 collagenase Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 7
- 238000002955 isolation Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 2
- 238000002689 xenotransplantation Methods 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 210000004153 islets of langerhan Anatomy 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000008188 pellet Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 7
- 229960005322 streptomycin Drugs 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 229940064804 betadine Drugs 0.000 description 3
- YALMXYPQBUJUME-UHFFFAOYSA-L calcium chlorate Chemical compound [Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O YALMXYPQBUJUME-UHFFFAOYSA-L 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- -1 L-(+)-Glutamine 2-aminoglutamic acid Chemical compound 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- NAIXASFEPQPICN-UHFFFAOYSA-O p-nitrophenylphosphocholine Chemical compound C[N+](C)(C)CCOP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 NAIXASFEPQPICN-UHFFFAOYSA-O 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- ZUYKJZQOPXDNOK-UHFFFAOYSA-N 2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one;hydrochloride Chemical compound Cl.C=1C=CSC=1C1(NCC)CCCCC1=O ZUYKJZQOPXDNOK-UHFFFAOYSA-N 0.000 description 1
- NJERAXSSDSHLGE-UHFFFAOYSA-N 4-(2-fluorophenyl)-1,3,8-trimethyl-6h-pyrazolo[3,4-e][1,4]diazepin-7-one;hydrochloride Chemical compound Cl.N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F NJERAXSSDSHLGE-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- PMAHNUOELLPJRS-UHFFFAOYSA-N CN1C(=O)N(C=2N=CNC2C1=O)CC(C)C.CN1C(=O)N(C=2N=CNC2C1=O)CC(C)C Chemical compound CN1C(=O)N(C=2N=CNC2C1=O)CC(C)C.CN1C(=O)N(C=2N=CNC2C1=O)CC(C)C PMAHNUOELLPJRS-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- OSILKTNFXJYZTB-UHFFFAOYSA-L calcium;dichlorate;dihydrate Chemical compound O.O.[Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O OSILKTNFXJYZTB-UHFFFAOYSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PKRPQASGRXWUOJ-UHFFFAOYSA-L dipotassium;dichloride Chemical compound [Cl-].[Cl-].[K+].[K+] PKRPQASGRXWUOJ-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960001594 tiletamine hydrochloride Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Definitions
- the present invention relates to a method for separating islets from newborn pigs, specifically (a) extracting the islets from newborn pigs; (b) injecting enzyme into the isolated pancreas; And (c) relates to a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
- pancreatic islet transplantation is a relatively simple treatment, less surgical complications, and can be transplanted repeatedly, which is particularly applicable to patients with type 1 diabetes.
- pancreatic islet transplantation is a relatively simple treatment, less surgical complications, and can be transplanted repeatedly, which is particularly applicable to patients with type 1 diabetes.
- pancreatic islets due to their rapid development and maturity, large numbers of offspring, organ size and physiological functions similar to humans, and the secretion of biologically active insulin in humans (Dufrane). et al., Transplant Rev (Orlando), 26 (3): 183-8, 2012).
- the study of the clinical application of xenograft islets to humans transplanting pig islets is considered an alternative to diabetes treatment (Samy et al., Xenotransplantation, 21 (3): 221-9, 2014).
- a technique for isolating high quality pig islets is an essential technique for xenograft transplantation, and research on this is required.
- the present inventors have diligently tried to develop an optimal pancreatic isolating technique, and as a result, it has been developed that the separation and culture and degree analysis technology of the new pig islets can be used to isolate high quality pancreatic islets with high yield.
- the present invention has been completed.
- the object of the present invention is to (a) extract the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) to provide a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
- the present invention comprises the steps of (a) extracting the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) provides a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
- pancreatic islet separation technique for cross-transplantation, as well as isolation and culture and degree of newborn pig islets.
- analytical techniques they can be widely used in biomedical fields such as diabetes treatment.
- Figure 1 shows the representative results observed after culturing the isolated NPCCs form by microscopic visual inspection for 1 day, 4 days and 7 days.
- Figure 2 shows the results of ATP activity analysis to confirm the viability of NPCCs.
- FIG. 3 shows the results of glucose-stimulated insulin secretion (GSIS) analysis to measure the insulin secretion function of NPCCs.
- GSIS glucose-stimulated insulin secretion
- the present invention relates to a method for separating high quality pancreatic islets from newborn pigs in high yield.
- the present invention in one aspect, (a) extracting the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) relates to a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
- the enzyme may be characterized in that the collagenase V (Sigma-Aldrich, MO, USA).
- the step (c) is preferably shaken in a 37 °C water bath may be characterized in that the activation of the enzyme.
- step (c) may be characterized in that it further comprises the step of culturing the islets, preferably characterized in that incubated in the presence condition of 5% carbon dioxide at 37 °C for 1 to 14 days. can do.
- F10 medium It may also be characterized by culturing in F10 medium.
- the composition of the F10 medium is shown in Table 1 below.
- the Hank balanced salt solution may be used as a buffer.
- the composition of the HBSS is shown in Table 2 below.
- Substance Tinnitus (common name) CAS number content(%) Calcium chlorate 10035-04-8 0.01 Magnesium Sulfate Nitrate Magnesium Sulphate, Heptahydrate 10034-99-8 0.001 Potassium chloride Potassium chloride 7447-40-7 0.004 Potassium phosphate monobasic Potassium Acid Phosphate 7778-77-0 0.006 Sodium chloride Sodium chloride 7647-14-5 0.8 Sodium Phosphate, Dibasic Disodium phosphate 7558-79-4 0.005 Dextrose D-glucose 50-99-7 0.1 Sodium bicarbonate Sodium bicarbonate 144-55-8 0.04 Penicillin-streptomycin, liquid 3810-74-0; 69-57-8 0.5 albumin Albuminz, Blood Serum 9048-46-8 0.25 Phenolic Red, Sodium Salt 34487-61-1 0.001 HEPES, free acid N- (2-hydroxyethyl) piperazine-N '-(2-
- the newborn pig may be characterized as being three days to five days old, but is not limited thereto.
- NPCCs Neonatal Porcine Pancreatic Cell Clusters
- Pancreatic cell clusters were isolated from 3 to 5 day old piglets (Landrace or Yorkshire), weighing approximately 1.0 to 2.0 kg. Several modifications have been made to known separation methods to isolate NPCCs (Korbutt GS et al., The Journal of clinical investigation, 97 (9): 2119-29, 1996).
- Newborn pigs were sequentially administered 0.1 mg / kg of azaferon (Stresnil, Janssen, Geneva, Belgium), 125 mg / kg of tiletamine hydrochloride, and zolazepam hydrochloride (Zoletil, Virbac, Carros, France). .
- a midline incision was used to open the newborn pigs for pancreatic exposure.
- the pancreas was carefully dissected from the surrounding pylorus, duodenum and artery. Special care has been taken to prevent bacterial infection, which may be caused by bowel nipping.
- the pancreas was cut into small pieces (1-2 mm 3 ) and Hank's balanced salt solution (Hank's) supplemented with 0.5% penicillin and streptomycin (Invitrogen, Carlsbad, USA), 0.25% bovine serum albumin (BSA) and 12.5 mM HEPES. rinsed in a balanced salt solution (HBSS).
- the tissues were then digested for exactly 11 minutes in a 37 ° C. water bath using 1.0 mg / mL collagenase V (Sigma-Aldrich, MO, USA). All the digested tissues were shaken vigorously by hand for 30 seconds until the color became milky white, and then the HBSS was added to stop the enzyme activity.
- the digested tissue was centrifuged at 450 xg for 1 minute. After resuspension, the degraded tissue was filtered through a stainless steel mesh (500 ⁇ m). The filtrate containing NPCCs was rinsed twice in HBSS. Finally, islet suspensions were supplemented with 10% adult porcine serum (APS; Gibco, Cat.No. 26250-084), 2% BSA, 0.1% ciprofloxacin and 1% penicillin and streptomycin (Ham's) F10 medium 37 Incubated in humidified air containing 5% CO 2 in the incubator. The islet islet suspension was placed in a 150 mm Petri dish for 7 days prior to the experiment. Culture medium was changed every other day. An algorithm was used to calculate 150 ⁇ m diameter pancreatic equivalent number (IEQ) (Cardona K et al., Nature medicine, 12 (3): 304-6, 2006).
- IEQ 150 ⁇ m diameter pancreatic equivalent number
- Isolated NPCCs were observed after culturing for 1, 4 and 7 days after separation using a microscope (Leica DFC 295) (FIG. 1). The average weight of the isolated islets was 1.73 ⁇ 0.45g.
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- Cell Titer-Glo reagent 319
- Cells were incubated for 30 minutes at room temperature to stabilize the luminescence signal.
- Luminescence was then recorded with a luminescence counter (VICTOR TM Light, PerkinElmer, Mass., USA).
- Luminescence indicates the metabolic activity of the cell. More than 90% (18 times / 20 times) of the separated NPCCs showed more than the reference value (red dotted line in FIG. 2) of the emission value corresponding to the NPCCs 100 IEQ,
- Example 3 Of NPCCs For measuring insulin secretory response rate Glucose -Stimulated insulin secretion ( GSIS ) analysis
- NPCCs insulin secretion response rate of the isolated NPCCs
- cells were cultured for 2 weeks and then subjected to GSIS analysis.
- the isolated islets were incubated on glucose at various concentrations.
- NPCCs were suspended and pre-incubated for 30 minutes in Krebs Ringer buffered HEPES (KRBB, pH 7.4).
- NPCCs were continuously incubated in low glucose (2.5 mM) buffer and then high glucose (20 mM) buffer in humidified air containing 5% CO 2 in 37 incubators for 1 hour.
- low glucose solution 2.5 mM
- high glucose solution 20 mM
- the concentration of insulin protein secreted in the buffer was measured using the DIAsource INS-Irma kit (DIAsource ImmunoAssays SA, Louvain-la-Neuve, Belgium) (Schroff RW et al., Cancer research, 45 (2): 879-85, 1985).
- the stimulation index (SI) value was calculated by dividing the amount of insulin secreted in the high glucose solution by the amount in the low glucose solution (Jung HS, Official journal of the Controlled Release Society, 172 (3): 1092-101, 2013). As a result, it was confirmed that the range of SI values was 1 to 1.5, which indicates normal insulin secretory function in response to different glucose stimuli (FIG. 3).
- NPCCs were separated by approximately 13,000 IEQ (13,539.45 ⁇ 5182.54 IEQ) per gram of pancreatic tissue (Table 3).
- NPCCs The parameters for the separation of NPCCs are as follows: date of separation, number of newborn pigs, age of newborn pig, weight of newborn pig, weight of pancreas (time / new pig), pancreatic weight before digestion, collagenase type (Cat.No. or Lot). No.), collagenase concentration, degradation time, total cell count measured on day 7, NPCCs yield (IEQ / new pig or IEQ / pancreatic weight gram) (Table 4).
- HTK solution containing 1% penicillin-streptomycin (P / S; 10,000 U / mL) and 1% gentamycin sulfate: lL of HTK solution was obtained from the infusion packet. After ingestion, 10 ml of penicillin and streptomycin (P / S) are added, 10 ml of gentamycin sulfate is added, and the samples are subdivided into tubes every 20 ml and stored in an ice box for the extracted pancreas.
- betadine in saline To 700 ml of saline solution, 300 ml of betadine (Povidone-iodine, Mundi Pharma) is added and then subdivided into 20 ml tubes to wash the extracted pancreas.
- Penicillin and streptomycin (Gibco, Cat. No. 15140-122).
- Ketamine (Imalgenem Gellini Farma-ceutici, Aprilia, Italy).
- PAD (Cat. No. B414A003-7011).
- the leaf paper The leaf paper.
- the isolated pancreas is stored in HTK solution and placed in an ice box until the separation of NPCCs begins.
- F-10 medium (pH 7.3) containing 10% adult pig serum, 1% P / S and 0.1% ciprofloxacin (Biosesang, Cat. No. F2014).
- Collagenase type V (collagenase derived from Clostridium histories) (Sigma, Cat. No. C9263).
- Steriplip-GP Filter Unit (0.22 ⁇ m) (MILLIPORE, Cat.No. SCGP00525).
- the extracted pancreas is placed in an empty conical tube and the individual pancreas is weighed (keep the same mark).
- the suspension is then passed through a 500 ⁇ m mesh sieve, rinsing the walls of each tube and again passing 30 ml HBSS through the mesh sieve.
- NPCCs isolated from one conical tube are divided into four 150 mm Petri dishes (medium volume 35 ml).
- NPCCs are obtained from four Petri-plates with four conical tubes.
- NPCCs are obtained from four Petri-plates with four conical tubes.
- pancreatic islet separation technique for cross-transplantation, as well as isolation and culture and degree of newborn pig islets.
- analytical techniques they can be widely used in biomedical fields such as diabetes treatment.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne un procédé d'isolement d'un îlot de porc nouveau-né et, plus spécifiquement, un procédé d'isolement d'un îlot de porc nouveau-né, le procédé comprenant les étapes suivantes : (a) extraire un îlot d'un porc nouveau-né ; (b) injecter une enzyme dans le pancréas ayant fait l'objet de l'extraction ; et (c) induire l'activation de l'enzyme. L'utilisation du procédé d'isolement d'un îlot selon la présente invention permet d'isoler un îlot de grande qualité d'un porc nouveau-né à un rendement élevé, et peut ainsi conduire à non seulement son utilisation à titre de technique d'isolement d'îlots pour xénogreffe, mais aussi au développement de techniques d'isolement, de culture et d'analyse de qualité d'un îlot de porc nouveau-né, et par conséquent, le procédé selon la présente invention peut être largement utilisé dans le domaine biomédical, tel que le traitement du diabète.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0166487 | 2016-12-08 | ||
KR1020160166487A KR101914837B1 (ko) | 2016-12-08 | 2016-12-08 | 신생돼지의 췌도 분리 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018105805A1 true WO2018105805A1 (fr) | 2018-06-14 |
Family
ID=62491227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/000273 WO2018105805A1 (fr) | 2016-12-08 | 2017-01-09 | Procédé d'isolement d'un îlot de porc nouveau-né |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101914837B1 (fr) |
WO (1) | WO2018105805A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114081694A (zh) * | 2021-12-15 | 2022-02-25 | 赛诺医疗科学技术股份有限公司 | 血管降解溶液、动物试验后血管内支架的获取方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039107A2 (fr) * | 1996-04-12 | 1997-10-23 | The Governors Of The University Of Alberta | Procede permettant d'accelerer la maturation des cellules |
KR100686383B1 (ko) * | 2005-08-17 | 2007-02-22 | 피더블유제네틱스코리아 주식회사 | 이종이식을 위한 돼지의 췌도세포 분리방법 |
KR20070095956A (ko) * | 2004-12-22 | 2007-10-01 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 췌장 소도의 분리방법 |
KR20130091260A (ko) * | 2010-07-13 | 2013-08-16 | 가부시키가이샤 오츠카 세이야쿠 고죠 | 췌도의 분리방법 및 췌도조직을 보호하기 위한 보호액 |
-
2016
- 2016-12-08 KR KR1020160166487A patent/KR101914837B1/ko active Active
-
2017
- 2017-01-09 WO PCT/KR2017/000273 patent/WO2018105805A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039107A2 (fr) * | 1996-04-12 | 1997-10-23 | The Governors Of The University Of Alberta | Procede permettant d'accelerer la maturation des cellules |
KR20070095956A (ko) * | 2004-12-22 | 2007-10-01 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 췌장 소도의 분리방법 |
KR100686383B1 (ko) * | 2005-08-17 | 2007-02-22 | 피더블유제네틱스코리아 주식회사 | 이종이식을 위한 돼지의 췌도세포 분리방법 |
KR20130091260A (ko) * | 2010-07-13 | 2013-08-16 | 가부시키가이샤 오츠카 세이야쿠 고죠 | 췌도의 분리방법 및 췌도조직을 보호하기 위한 보호액 |
Non-Patent Citations (1)
Title |
---|
PARK, SOL JI ET AL.: "Functional Improvement of Porcine Neonatal Pancreatic Cell Clusters via Conformal Encapsulation Using an Air-driven Encapsulator", EXPERIMENTAL AND MOLECULAR MEDICINE, vol. 44, no. 1, January 2012 (2012-01-01), pages 20 - 25, XP055510111 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114081694A (zh) * | 2021-12-15 | 2022-02-25 | 赛诺医疗科学技术股份有限公司 | 血管降解溶液、动物试验后血管内支架的获取方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
KR101914837B1 (ko) | 2018-11-02 |
KR20180065512A (ko) | 2018-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Encapsulated three-dimensional culture supports development of nonhuman primate secondary follicles | |
JP2813467B2 (ja) | 細胞培養法および培地 | |
Nagata et al. | Evaluation of insulin secretion of isolated rat islets cultured in extracellular matrix | |
Gouk et al. | Cryopreservation of mouse testicular tissue: prospect for harvesting spermatogonial stem cells for fertility preservation | |
CN106520676B (zh) | 从人胎盘羊膜制备人羊膜上皮细胞的方法及其应用 | |
WO1991009936A1 (fr) | Produit cellulaire progeniteur neuronal proliferee et procede | |
JPH09509827A (ja) | 機能性ヒト組織の再生と利用 | |
WO2020111507A1 (fr) | Composition pour la transplantation d'organoïde | |
WO2013085303A1 (fr) | Cellules souches multipotentes dérivées de la membrane amniotique canine | |
WO2018105805A1 (fr) | Procédé d'isolement d'un îlot de porc nouveau-né | |
Abraham et al. | In vitro culture of Dirofilaria immitis third-and fourth-stage larvae under defined conditions | |
Velasco et al. | Rat pancreatic beta-cell culture | |
ES2299417T3 (es) | Metodo para producir preparaciones de celulas endocrinas pancreaticas madura e inmaduras, preparacion de las celulas y su utilizacion para el tratamiento de la diabetes mellitus. | |
Mansour et al. | The impact of spermatozoa preincubation time and spontaneous acrosome reaction in intracytoplasmic sperm injection: a controlled randomized study | |
WO2013077639A1 (fr) | Cellules souches mésenchymateuses issues d'une membrane amniotique équine | |
BRPI0708039A2 (pt) | células alimentadoras derivadas de células-tronco de tecido | |
WO2019216450A1 (fr) | Procédé de culture de cellules souches sécrétant des composants anti-inflammatoires, et composition anti-inflammatoire contenant ledit milieu de culture de cellules souches | |
WO2018092962A1 (fr) | Échafaudage générateur d'oxygène et procédé de production dudit échafaudage | |
WO2017078439A1 (fr) | Composition pharmaceutique pour le traitement du diabète, comprenant des cellules d'îlots pancréatiques et une matrice extracellulaire artificielle de type élastine | |
US8372644B2 (en) | Method for growing adult cells | |
WO2020130615A1 (fr) | Composition de milieu pour induire la différenciation de cellules souches hépatiques en cholangiocytes et utilisation de cette composition | |
WO2014119893A1 (fr) | Procédé pour induire des cellules souches pluripotentes sur mesure au moyen d'un extrait de cellules souches végétales ou de cellules souches dédifférenciées végétales, et cellules souches pluripotentes produites au moyen du procédé | |
Shenvi et al. | A rat primary hepatocyte culture model for aging studies | |
CN106609258A (zh) | 一种大鼠鼻粘膜上皮细胞分离及培养方法 | |
Galas | Primary culture of ovarian cells for research on cell interactions in the hormonal control of steroidogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17879618 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17879618 Country of ref document: EP Kind code of ref document: A1 |